Short Interest in Invivyd, Inc. (NASDAQ:IVVD) Increases By 72.8%

Key Points

• Short interest in Invivyd, Inc. increased by 72.8% in August, rising to 5.27 million shares.
• Analysts have mixed perspectives, with D. Boral Capital lowering their target price from $3.00 to $1.00 while HC Wainwright maintains a "buy" rating with a $5.00 target.
• Invivyd shares experienced a 10.5% decrease in trading, reaching $1.28, following disappointing earnings results that missed revenue estimates by over $11 million.

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 5,270,000 shares, a growth of 72.8% from the August 15th total of 3,050,000 shares. Based on an average daily trading volume, of 5,130,000 shares, the short-interest ratio is presently 1.0 days. Currently, 4.2% of the shares of the company are sold short. Currently, 4.2% of the shares of the company are sold short. Based on an average daily trading volume, of 5,130,000 shares, the short-interest ratio is presently 1.0 days.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. D. Boral Capital lowered their target price on shares of Invivyd from $3.00 to $1.00 and set a "buy" rating for the company in a research note on Monday, August 25th. HC Wainwright reiterated a "buy" rating and issued a $5.00 price target on shares of Invivyd in a report on Wednesday, August 27th. One investment analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company. According to MarketBeat, Invivyd currently has a consensus rating of "Buy" and a consensus target price of $3.18.

Invivyd Trading Down 10.5%

NASDAQ IVVD traded down $0.15 during trading hours on Monday, reaching $1.28. 2,728,107 shares of the company traded hands, compared to its average volume of 7,940,498. The company has a 50 day moving average of $0.83 and a two-hundred day moving average of $0.76. The stock has a market capitalization of $153.78 million, a PE ratio of -1.39 and a beta of 0.55. Invivyd has a 12 month low of $0.35 and a 12 month high of $2.74.

Invivyd (NASDAQ:IVVD - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The company had revenue of $11.79 million during the quarter, compared to the consensus estimate of $23.16 million. Invivyd had a negative return on equity of 177.89% and a negative net margin of 238.33%. On average, equities research analysts anticipate that Invivyd will post -1.64 earnings per share for the current year.

Insider Buying and Selling at Invivyd

In related news, insider Jill Andersen sold 49,402 shares of the firm's stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $0.57, for a total value of $28,159.14. Following the completion of the sale, the insider owned 84,446 shares in the company, valued at $48,134.22. This trade represents a 36.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 277,654 shares of company stock worth $167,215 in the last three months. 25.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Invivyd

Several institutional investors and hedge funds have recently bought and sold shares of the business. 683 Capital Management LLC raised its stake in Invivyd by 2.3% during the second quarter. 683 Capital Management LLC now owns 3,070,000 shares of the company's stock worth $2,195,000 after acquiring an additional 70,000 shares during the period. Deutsche Bank AG grew its position in Invivyd by 35.2% in the 4th quarter. Deutsche Bank AG now owns 874,406 shares of the company's stock worth $385,000 after purchasing an additional 227,463 shares during the last quarter. AQR Capital Management LLC grew its position in Invivyd by 2,051.0% in the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company's stock worth $249,000 after purchasing an additional 391,617 shares during the last quarter. Two Sigma Investments LP grew its position in Invivyd by 125.3% in the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company's stock worth $163,000 after purchasing an additional 204,188 shares during the last quarter. Finally, Two Sigma Advisers LP grew its position in Invivyd by 1,276.5% in the 4th quarter. Two Sigma Advisers LP now owns 304,200 shares of the company's stock worth $135,000 after purchasing an additional 282,100 shares during the last quarter. Institutional investors and hedge funds own 70.36% of the company's stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.